Stent bioactivo de titanio y oxido nitrico, ? ´ s seguro y eficaz que los stents farmacoactivos de segunda generacion? Nitric-oxide Coated Bioactive Titanium Stents: Safer and More Effective Than Second-generation Drug-eluting Stents?

[1]  J. Fernández-Díaz,et al.  Estudio aleatorizado para comparar el stent bioactivo de titanio con el stent de everolimus en pacientes diabéticos (TITANIC XV), resultados a 1 año , 2014 .

[2]  G. Stone,et al.  Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. , 2013, Journal of the American College of Cardiology.

[3]  F. Alfonso.  Nuevos stents farmacoactivos: ¿sin polímero, con polímeros biodegradables o dispositivos completamente bioabsorbibles? , 2013 .

[4]  P. Serruys,et al.  Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial , 2012, The Lancet.

[5]  M. Niemelä,et al.  A prospective randomised comparison of titanium-nitride-oxide-coated bioactive stents with everolimus-eluting stents in acute coronary syndrome: the BASE-ACS trial. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[6]  Deepak L. Bhatt,et al.  Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents: A Mixed-Treatment Comparison Analysis of 117 762 Patient-Years of Follow-Up From Randomized Trials , 2012, Circulation.

[7]  Patrick W Serruys,et al.  Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? , 2012, European heart journal.

[8]  P. Serruys,et al.  Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[9]  A. Kastrati,et al.  Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with Diabetes mellitus: a patient-level meta-analysis of randomized trials , 2011, Clinical Research in Cardiology.

[10]  S. Windecker,et al.  Drug-eluting stents: limitations of early generation and progress with newer generation devices. , 2010, Minerva medica.

[11]  M. Niemelä,et al.  Two-year follow-up after percutaneous coronary intervention with titanium-nitride-oxide-coated stents versus paclitaxel-eluting stents in acute myocardial infarction , 2009, Annals of medicine.

[12]  B. Gersh,et al.  Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.

[13]  I. Tamari,et al.  The Titanium-NO Stent:results of a multicenter registry. , 2006, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[14]  Patrick W Serruys,et al.  Coronary-artery stents. , 2006, The New England journal of medicine.

[15]  P. Serruys,et al.  The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial. , 2014, JACC. Cardiovascular interventions.

[16]  Emilio Cuesta-López,et al.  Resultados comparativos entre el stent metálico y el stent bioabsorbible a los dos años de su implante , 2014 .